TASE Promotes the Life Science Industries: “Analysis of Healthcare Companies” TASE Co-sponsors New LAHAV Program at Tel Aviv University's Faculty of Management

Press Release
18/11/2010
 

LAHAV Executive Education at Tel Aviv University’s Faculty of Management in cooperation with the Tel Aviv Stock Exchange (TASE) is opening a program of studies on The Analysis of Healthcare Companies on December 15, 2010. The academic director of the program is Dr. Itay Kama.

Elah Alkalay, V.P. of business development at I.B.I.  Investment House is responsible for the professional content. Ruth Alon, Chairperson of the Israel Life Science Industry Organization (ILSI), is the professional advisor. The objective of the program is to train participants in conducting financial analysis of the life science industries.

 

In recent years the life science industries have played an increasingly important role in the world's and Israel's economy. In-depth analysis of companies operating in this field requires proficiency in financial statement analysis and corporate valuation, as well as familiarity with the complex professional concepts and processes of the life science industries. The program is designed to impart knowledge on fundamental life science concepts and the tools of financial analysis, in an effort to convey an understanding of the linkage between disclosure in financial statements and the operational and financial performance of life science companies. The course is targeted at analysts, economists and corporate managers.

 

Subjects Covered in the Program:
 

Life Sciences:

·         Fundamental concepts: cell structure and activity, chemistry vs. biology, the immune system, oncology, cardiology, metabolic diseases, central nervous system

·         The process of drug, medical device and diagnostic product development.

·         Pharmaceutical and medical device patents.

·         Regulation, FDA approval, Japan and the emerging markets, reimbursement for pharmaceuticals.

·         The structure of life science markets.

 

Finance:

·         The analysis of financial statements of life science companies.

·         Corporate valuation methodologies.

·         Case studies of life science companies.
 

Ronit Harel Ben-Zeev, Senior V.P. and Head of the TASE Economics Department views the development of a cadre of biomed financial analysts as vital to Israel’s capital market and the growth of its life science industries. “TASE’s biomed sector has gained momentum over the past five years and currently some 51 medical devices, drug development and biomed investment companies trade on TASE. Since the beginning of 2010, 12 additional companies have joined the pipeline of potential biomed IPOs and are currently in various stages of going public on TASE. Financial analysis is an essential part of the infrastructure investors build on, and accordingly, it contributes substantially to the transparency of companies operating in this highly complex sector. TASE has placed the publicly traded high-tech industries, including the biomed sector, high on its list of priorities. For this reason, TASE is working to enhance the infrastructure necessary to facilitate the growth of this sector on the local market. In this context we are collaborating with LAHAV in order to promote the training of analysts with a background in life sciences, who can proficiently track TASE-listed companies.”

 

Udi Aharoni, LAHAV CEO, concurs: “This program is yet another addition to the body of knowledge and the tools we are developing for managing the life science industries. Today few capital market professionals clearly understand the complexities of this increasingly important sector of the economy. Our partnership with TASE in this program of studies aims to promote the sector for the benefit of the entire economy.”